Lunesta (Eszopiclone) Patent Expiration, LOE Window & CMS Spending

Lunesta (Eszopiclone) by Waylis Therapeutics: Off-Patent Genericized (AB Competition), 9 AB generics, $6.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorWaylis Therapeutics
FDA Application & PathwayN021476 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$6.0M
2024 Medicare Part D Spend$5.9M
2024 Medicaid Spend$86K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel